Gossamer Bio, Inc. (GOSS) stock
GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.43+0.39 (+3.53%)
Close on Nov 18, 2026Market cap $5.59BP/E –Yield –
Gossamer Bio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Gossamer Bio's revenue for the twelve months ending Jun 30, 2026 was $53.29M, up 32.4% year over year. For fiscal 2025 it was $48.47M, down 57.7% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.47M | -57.7% |
| FY2024 | Dec 31, 2024 | $114.70M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
| FY2022 | Dec 31, 2022 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.24M | -19.6% |
| Q1 FY2026 | Mar 31, 2026 | $16.96M | +71.5% |
| Q4 FY2025 | Dec 31, 2025 | $13.80M | +47.1% |
| Q3 FY2025 | Sep 30, 2025 | $13.29M | +40.2% |
| Q2 FY2025 | Jun 30, 2025 | $11.49M | -88.0% |
| Q1 FY2025 | Mar 31, 2025 | $9.89M | – |
| Q4 FY2024 | Dec 31, 2024 | $9.38M | – |
| Q3 FY2024 | Sep 30, 2024 | $9.48M | – |
| Q2 FY2024 | Jun 30, 2024 | $95.84M | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?